It's too soon to know if the trend will last. But health providers fear the national discourse around vaccines could yield more sickness and death this winter.

You recently posted a couple of articles about the respiratory syncytial virus (RSV) vaccine and the benefits versus the ...

A number of diseases tend to peak in the winter, thanks to indoor gatherings that help germs spread. The list includes not ...

Researchers evaluated the real-world effectiveness of nirsevimab in preventing ICU admission and acute respiratory failure associated with RSV among infants.

GSK said on Friday a panel of the European Medicines Agency had backed the use of its respiratory syncytial virus (RSV) ...

An expert panel of the European Medicines Agency (EMA) has endorsed expanding the marketing authorization for Arexvy, a ...

Federal regulators have begun a safety review of two RSV medicines used to protect infants, even though no safety problems ...

Respiratory syncytial virus, commonly known as RSV, is often associated with cold-like symptoms in young children.

Nearly 1,000 flu cases have been reported to the Erie County Department of Health since Oct. 1 but only seven RSV cases have ...

FDA turns up the heat: Federal regulators are requesting more safety information from drugmakers on products meant to protect ...

Morning! Today, we preview a contentious generic drug dispute that may end up at the Supreme Court, discuss how the FDA’s new stance on vaccines could impact RSV shots, and more.